Otivio extends exploratory MS clinical trial with FlowOx

EXECUTIVE SUMMARY

After Otivio came across a significant discovery for a potential new application for their device FlowOxTM 2.0, they have decided to extend their exploratory clinical trial to analyze and understand the functionality of the device for patients with Multiple Sclerosis (pwMS).

Screenshot from Health Tech World April 2022

The trial follows a recent case series of 7 pwMS conducted by neurologist Dr Gabriela Fortes where FlowOx significantly alleviated MS related spasticity and pain.

You can read the article in full here!

If you would like to know more about our progress or our product, please contact us at projectmyelin@flowox.com 

Scroll to Top